RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial – JAMA

Commentary: Semaglutide paired with intensive behavioral therapy showed triple weight loss vs placebo – University of Pennsylvania School of Medicine

Related study: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults – New England Journal of Medicine (study and commentary)

Commentary on Twitter

In this RCT, once-weekly subcutaneous semaglutide used as an adjunct to intensive behavioral therapy & low-calorie diet led significantly greater weight loss vs placebo over 68 weeks among adults w #overweight or #obesity w/o #diabetes https://t.co/xFedvckUUj @PennMedicine #STEP3

— JAMA (@JAMA_current) February 24, 2021